Urolithin A is a gut-microbiota-derived ellagitannin metabolite studied in humans for anti-aging research contexts, including mitochondrial function, muscle health, immune aging, cardiometabolic markers, gut-microbiota variability, bioavailability, and short-term safety (Research) (Review).
Urolithin A is widely searched in relation to “anti-aging” because human studies have examined biological processes that change with age, especially mitochondrial quality control, muscle endurance, immune-cell aging, and physical-function biomarkers (Research) (Research). The strongest human evidence does not show that Urolithin A extends human lifespan; instead, it shows measurable bioavailability, short-term tolerability, and effects on selected aging-related biomarkers and muscle-function outcomes (Research) (Review). Human evidence is best described as emerging-to-moderate because multiple randomized trials exist, but many studies are short, modest in size, and focused on surrogate endpoints rather than long-term aging or disease outcomes (Review).
Ingredient Identity
- Official name(s): Urolithin A.
- Synonyms: UA; 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one.
- Classification: Gut-microbiota-derived ellagitannin metabolite; dibenzo-α-pyrone-type polyphenol metabolite (Review).
- CAS number: Not established from the approved source set.
- Endogenous vs exogenous: Urolithin A is produced in the body only after gut microbes metabolize dietary ellagitannins, and it has also been studied as a directly consumed oral ingredient (Research).
Ingredient Snapshot
- Classification: Urolithin A is a microbial metabolite formed from ellagitannin-rich foods and studied as a direct oral ingredient in human trials (Research).
- Endogenous vs exogenous status: It can be generated inside the gut after dietary precursor intake, but direct Urolithin A intake bypasses the need for microbial conversion from foods such as pomegranate (Research).
- Primary human research domains: Human studies focus on Aging and Longevity Research, Muscle Health, Immune System, Cardiovascular Health, and Digestive and Gastrointestinal Health (Research) (Research).
- Anti-aging relevance: Urolithin A is an anti-aging research ingredient because trials examine age-associated biology such as mitochondrial quality control, muscle endurance, immune-cell phenotypes, and metabolic biomarkers rather than lifespan itself (Research) (Review).
- Common study formats: The evidence includes randomized controlled trials of direct Urolithin A, crossover bioavailability studies, dietary ellagitannin interventions, and systematic reviews of human trials (Research) (Review).
- Pharmacokinetic characterization status: Oral Urolithin A is bioavailable in humans, and circulating or urinary Urolithin A metabolites can be measured after direct intake or ellagitannin precursor intake (Research) (Research).
- Regulatory context (U.S./EU): In the United States, FDA GRAS Notice GRN 791 records a “no questions” response for specified food uses of Urolithin A, while FDA states that such a response is not an FDA affirmation under 21 CFR 170.35 (FDA) (FDA). In the European Union, Urolithin A appears in European Commission novel-food application materials, and the approved source set does not establish broad EU Union-list authorization for Urolithin A (EFSA).
- Evidence maturity: Human evidence is emerging-to-moderate for anti-aging-related biomarkers and muscle outcomes, but limited for direct human longevity outcomes (Review).
Introduction
Urolithin A is a compound produced when gut microbes transform ellagitannins, a class of plant polyphenols found in pomegranate, walnuts, and related dietary sources studied in humans (Research) (Research). In nutrition and anti-aging research, Urolithin A is important because not all people make the same amount from food; this difference is often described through “urolithin metabotypes,” which reflect microbial conversion patterns after ellagitannin intake (Research).
Most public interest in Urolithin A centers on anti-aging and longevity because human trials have studied mitochondrial biomarkers, skeletal-muscle endurance, immune-cell aging markers, and physical-function measures in middle-aged and older adults (Research) (Research). The key distinction is that Urolithin A has not been shown to extend human lifespan; the human evidence is about aging-related biology, especially mitochondrial quality control and functional biomarkers that are relevant to healthy aging research (Research) (Review).
This article is informational only, describes Urolithin A as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- Urolithin A is a gut-microbiota-derived metabolite studied in humans for anti-aging-related biology, especially mitochondrial quality control, muscle endurance, immune-cell aging markers, and bioavailability (Research) (Research).
- Urolithin A should not be described as proven to extend human lifespan; current human evidence focuses on aging-related biomarkers and function-related outcomes rather than longevity endpoints (Review).
- The most developed human research area is Muscle Health, where randomized trials have examined muscle endurance, strength, mitochondrial biomarkers, and physical-function endpoints (Research) (Review).
- Direct oral Urolithin A is bioavailable in humans and has been studied at repeated daily doses ranging from 10 mg/day to 1,000 mg/day, with single-dose exposure studied up to 2,000 mg (Research) (Research).
- Dietary sources such as pomegranate and walnuts provide ellagitannin precursors, but Urolithin A formation from these foods depends on gut-microbiota conversion and varies across individuals (Research).
- Evidence for Cardiovascular Health is mixed, with one endothelial-function trial reporting microbiota-linked signals and one heart-failure crossover trial reporting no clear positive effect on measured indices (Research) (Research).
- Short-term safety findings are generally reassuring in studied populations, but larger and longer trials are needed to assess uncommon adverse events, population-specific cautions, and long-term use (Research) (Review).
Human Research Findings by Condition
Aging and Longevity Research
Human Aging and Longevity Research is the central evidence area for Urolithin A because studies examine age-relevant mechanisms such as mitochondrial quality control, muscle endurance, immune-cell aging, and metabolic biomarkers (Research) (Research). The current evidence does not demonstrate human lifespan extension; it supports biological activity in aging-related systems and selected functional outcomes over weeks to months (Research) (Review).
Key human study
Dose studied: Single doses of 250–2,000 mg; repeated doses of 250–1,000 mg/day
Population: Healthy sedentary older adults
Duration: Single-dose phase and 4-week repeated-dose phase
The first-in-human trial evaluated Urolithin A in older adults and measured safety, plasma exposure, acylcarnitines, and skeletal-muscle mitochondrial gene-expression markers. Urolithin A was bioavailable across tested doses, and repeated 500 mg/day and 1,000 mg/day dosing modulated mitochondrial and cellular-health biomarkers in skeletal muscle (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 500 mg/day and 1,000 mg/day
Population: Middle-aged adults
Duration: 4 months
A randomized clinical trial in middle-aged adults studied direct Urolithin A exposure and measured plasma metabolites, leg-muscle strength, and exercise-related outcomes. The study reported dose-dependent metabolite increases and improvements in leg-muscle strength and selected exercise-related measures, making it relevant to healthy-aging research but not a direct test of lifespan extension (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Muscle Health
Human Muscle Health research is the most developed clinical area for Urolithin A because several trials measured muscle endurance, strength, physical function, and mitochondrial biomarkers (Research) (Research). The overall signal is mixed-to-promising: some studies report improvements in secondary muscle-endurance or strength endpoints, while broader physical-function outcomes are not consistently positive (Review).
Key human study
Dose studied: 1,000 mg/day
Population: Adults aged 65–90 years
Duration: 4 months
A randomized clinical trial tested daily Urolithin A in older adults and measured 6-minute-walk distance, ATPmax, muscle endurance, mitochondrial biomarkers, and safety. The study did not find clear improvement in its primary 6-minute-walk distance or ATPmax endpoints, but it reported improvements in secondary muscle-endurance and biomarker outcomes (Research).
Result: Human clinical studies reported mixed findings
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 1 g/day
Population: Resistance-trained male athletes
Duration: 8 weeks
A randomized, double-blind, placebo-controlled trial in resistance-trained men examined strength, endurance, oxidative-stress markers, inflammatory markers, and protein-metabolism markers during training. The study reported improvements in selected strength and endurance outcomes and reductions in oxidative-stress and inflammation markers, but interpretation is limited to a trained male athletic population and a short intervention period (Research).
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Immune System
Human Immune System research on Urolithin A is directly relevant to the anti-aging discussion because immune-cell composition and function change with age (Research). Current evidence is early and biomarker-based, so it should be interpreted as immune-aging research rather than proof of improved immunity or infection resistance (Research).
Key human study
Dose studied: 1,000 mg/day
Population: Healthy middle-aged adults
Duration: 4 weeks
A randomized placebo-controlled proof-of-concept trial examined T-cell subpopulations, immune metabolism, mitochondrial content, cytokines, and immune-cell function after Urolithin A supplementation. The study reported changes in CD8+ T-cell phenotypes, fatty-acid oxidation capacity, mitochondrial biogenesis signals, NK-cell and monocyte subsets, and selected immune-cell functional readouts (Research).
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Cardiovascular Health
Human Cardiovascular Health evidence is relevant to aging research because vascular function and cardiometabolic markers often change across adulthood, but Urolithin A findings are mixed (Research) (Research). One low-dose trial reported microbiota-linked endothelial and diversity signals, while a heart-failure crossover trial did not support clear improvement in measured heart-failure indices (Research).
Key human study
Dose studied: 10 mg/day and 50 mg/day
Population: Low-Urolithin-A producers with relatively poor vascular endothelial function
Duration: 12 weeks
A randomized placebo-controlled trial examined whether low-dose direct Urolithin A affected vascular endothelial function and gut microbiota. The 50 mg/day group showed increased gut microbial alpha diversity, and endothelial response appeared related to baseline gut-microbiota patterns rather than a uniform effect across all participants (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Direct Urolithin A in a randomized crossover design
Population: People with heart failure with reduced ejection fraction
Duration: Duration not specified in the approved evidence summary
A randomized double-blind crossover trial tested Urolithin A in participants with heart failure with reduced ejection fraction and examined echocardiographic and biochemical indices. The study did not support a clear positive effect of Urolithin A on the measured heart-failure outcomes (Research).
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Digestive and Gastrointestinal Health
Human Digestive and Gastrointestinal Health research is important for Urolithin A because gut microbes determine whether ellagitannin-rich foods are converted into Urolithin A metabolites (Research). This means anti-aging claims based on pomegranate, walnuts, or other ellagitannin-rich foods cannot be assumed to produce the same exposure in every person (Research).
Key human study
Dose studied: Walnut, pomegranate-extract, and mixed-nut dietary exposures
Population: Normoweight, overweight-obese, and metabolic-syndrome populations
Duration: Varied across dietary interventions
A human study across dietary interventions examined urolithin metabotypes after intake of walnut, pomegranate extract, and mixed nuts. The study reported that metabotype patterns differed across participants and were associated with cardiometabolic-risk biomarkers, supporting gut-microbiota conversion as a key driver of Urolithin A exposure from foods (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Pomegranate extract
Population: Healthy overweight-obese adults
Duration: Duration not specified in the approved evidence summary
A randomized placebo-controlled pomegranate-extract trial examined cardiovascular-risk biomarkers and urolithin metabotypes. The study reported that urolithin metabotypes helped explain interindividual variability in biomarker responses after pomegranate ellagitannin intake (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Cancer Research
Human Cancer Research evidence for Urolithin A is limited and indirect in the approved source set. The available human evidence comes from dietary walnut research examining Urolithin A formation, inflammation, and colon-polyp immune microenvironment markers rather than isolated Urolithin A as a cancer intervention (Research).
Key human study
Dose studied: Walnut dietary intervention
Population: Participants in a walnut intervention study with colon-polyp immune marker assessment
Duration: Duration not specified in the approved evidence summary
A walnut intervention study assessed urolithin formation, inflammatory markers, and immune features of the colon-polyp microenvironment. Higher Urolithin A formation after walnut intake was associated with lower inflammatory markers and altered immune microenvironment markers in colon polyps, but the study does not establish that isolated Urolithin A treats or prevents cancer (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human Urolithin A exposure in anti-aging research comes from two different pathways: dietary ellagitannin precursors and direct Urolithin A intake (Research). Dietary precursor studies are relevant because foods such as pomegranate and walnuts can lead to Urolithin A metabolite formation, but microbial conversion varies across individuals (Research). Direct Urolithin A studies are more useful for interpreting anti-aging biomarker research because they provide known ingredient amounts and measurable plasma metabolite exposure (Research). The dose bands below describe exposures studied in humans and are not dosing recommendations.
180 mL pomegranate juice concentrate:
This was the lowest documented human exposure in the approved evidence set. Healthy volunteers consumed pomegranate juice concentrate, and researchers measured urinary metabolites afterward. Urolithin A glucuronide appeared in urine, showing that dietary ellagitannins can be converted into Urolithin A metabolites in humans. Urinary metabolites persisted up to 48 hours in some participants, which supports delayed microbial production after food-based precursor intake rather than immediate direct Urolithin A delivery (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This was a dietary precursor exposure and cannot be translated into an equivalent direct Urolithin A dose.
8 oz pomegranate juice:
An 8 oz pomegranate juice challenge was studied as a dietary precursor comparator against a direct 500 mg Urolithin A food product. Direct Urolithin A produced substantially higher plasma Urolithin A metabolite exposure than pomegranate juice. This finding is important for anti-aging interpretation because eating ellagitannin-rich foods may not produce the same Urolithin A exposure as direct ingredient administration. The result also shows why gut-microbiota conversion is a major source of variability in food-based Urolithin A research (Research).
Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: Pomegranate juice provides precursors, not a controlled direct Urolithin A amount.
8 oz pomegranate liquid extract and 1,000 mg pomegranate powder extract:
A human comparison study evaluated pomegranate juice, liquid extract, and powder extract formats. The study reported broadly similar urinary Urolithin A glucuronide levels across these pomegranate-derived formats. This supports the idea that multiple ellagitannin-containing pomegranate formats can lead to Urolithin A metabolite formation. The study does not establish clinical anti-aging effects from those formats (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: The measured endpoint was urinary metabolite production, not a longevity or clinical aging endpoint.
250 mg and 1,000 mg pomegranate extract:
A single-dose pomegranate-extract pharmacokinetic study used 250 mg and 1,000 mg pomegranate extract exposures. Researchers developed and applied LC-MS/MS methods to quantify ellagitannin-related metabolites, including urolithin-related pharmacokinetics. This evidence helps explain food-extract metabolism but does not represent direct isolated Urolithin A dosing. It is most useful for understanding how precursor extracts contribute to variable Urolithin A metabolite exposure (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: The exposure was pomegranate extract, not isolated Urolithin A.
800 mg standardized pomegranate extract:
An acute human study used 800 mg standardized pomegranate extract and measured plasma and urinary metabolites. The metabolite profile included Urolithin A and conjugated Urolithin metabolites after intake. This supports the biological pathway from ellagitannin precursor intake to Urolithin A metabolite formation. It does not show that 800 mg pomegranate extract is equivalent to 800 mg Urolithin A (Research).
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: This study supports metabolite formation, not anti-aging efficacy.
10 mg/day direct Urolithin A:
A randomized placebo-controlled trial studied 10 mg/day direct Urolithin A for 12 weeks in low-Urolithin-A producers with relatively poor vascular endothelial function. This was the lowest direct daily Urolithin A dose in the approved evidence set. The study examined vascular endothelial function and gut microbiota, but the approved evidence summary does not identify a clear standalone clinical effect for the 10 mg/day group. This dose is relevant because it shows that low-dose direct Urolithin A has been studied in a selected human population (Research).
Result: Inconclusive
Evidence strength: Emerging
Notes / limitations: The population was selected for low Urolithin A production and relatively poor endothelial function.
50 mg/day direct Urolithin A:
The same 12-week trial also studied 50 mg/day direct Urolithin A. The 50 mg/day group showed increased gut microbial alpha diversity, and endothelial response appeared related to baseline gut-microbiota patterns. This is relevant to anti-aging research because vascular function and gut microbiota are commonly studied in aging biology. The evidence remains preliminary because the study was small and exploratory (Research).
Result: Modest improvement
Evidence strength: Emerging
Notes / limitations: This does not establish broad cardiovascular or anti-aging benefit.
250–2,000 mg single doses and 250–1,000 mg/day repeated direct Urolithin A:
The first-in-human clinical trial tested direct Urolithin A across single doses of 250–2,000 mg and repeated daily doses of 250–1,000 mg/day. Urolithin A was bioavailable in plasma at all tested doses. In the repeated-dose phase, 500 mg/day and 1,000 mg/day for 4 weeks modulated plasma acylcarnitines and skeletal-muscle mitochondrial gene-expression markers. This is one of the most important anti-aging research dose bands because it directly connects Urolithin A exposure with mitochondrial and cellular-health biomarkers in older adults (Research).
Result: Preliminary signal
Evidence strength: Moderate
Notes / limitations: The study supports short-term biomarker target engagement, not lifespan extension.
500 mg/day direct Urolithin A:
A randomized clinical trial in middle-aged adults studied 500 mg/day direct Urolithin A for 4 months. The study reported dose-dependent plasma metabolite increases and improvements in leg-muscle strength and selected exercise-related endpoints. This dose is relevant to healthy-aging research because muscle strength and function are common age-associated outcomes. The same 500 mg exposure also produced higher plasma Urolithin A metabolite levels than an 8 oz pomegranate juice challenge in a bioavailability comparison (Research) (Research).
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The evidence comes from a 4-month study and should not be interpreted as proof of anti-aging efficacy.
1,000 mg/day direct Urolithin A:
Direct 1,000 mg/day Urolithin A has been studied in older adults, middle-aged adults, healthy middle-aged adults in immune-aging research, runners, and soccer players. In older adults, 1,000 mg/day for 4 months did not clearly improve primary 6-minute-walk distance or ATPmax endpoints, but it improved some secondary muscle-endurance and biomarker outcomes. In immune-aging research, 1,000 mg/day for 4 weeks altered T-cell phenotypes and immune-metabolic markers. This dose is the most frequently represented direct Urolithin A exposure in the approved anti-aging-related human evidence (Research) (Research).
Result: Mixed findings
Evidence strength: Moderate
Notes / limitations: Results differ by population and endpoint.
1 g/day direct Urolithin A:
A resistance-training study used 1 g/day Urolithin A for 8 weeks in male athletes. The study reported improvements in selected strength and endurance outcomes and reductions in oxidative-stress and inflammation markers. A runner study using 1,000 mg/day for 4 weeks did not significantly improve a 3,000-m time-trial endpoint but reported lower perceived exertion and creatine-kinase exposure versus placebo. These studies are relevant to performance and recovery, but they are not direct evidence of longevity or disease prevention (Research) (Research).
Result: Mixed findings
Evidence strength: Emerging
Notes / limitations: Athletic outcomes vary by sport, training context, and endpoint.
Key Takeaways from Human Research
- Urolithin A is most credible as an anti-aging research ingredient when framed around mitochondrial quality control, muscle function, immune-cell aging markers, and bioavailability rather than lifespan extension (Research) (Research).
- The most developed human evidence is in Muscle Health, where trials report mixed but meaningful signals across endurance, strength, mitochondrial biomarkers, and physical-function endpoints (Research) (Review).
- Direct oral Urolithin A produces more controlled exposure than dietary ellagitannin precursors, because foods require gut microbial conversion before Urolithin A metabolites appear (Research).
- Dietary pomegranate and walnut studies are important for natural-occurrence context, but they should not be treated as equivalent to direct Urolithin A supplementation trials (Research) (Research).
- Cardiovascular and immune-aging findings are promising but early, with endpoint-specific signals that require replication in larger and longer trials (Research) (Research).
- Current safety findings are generally reassuring over studied durations, but long-term safety and population-specific evidence remain incomplete (Research) (Review).
Origin & Natural Occurrence
Urolithin A is not simply “found” in foods in the same way vitamins or minerals are usually described. It is mainly produced when gut microbes metabolize ellagitannins from foods and food-derived materials such as pomegranate and walnuts (Research) (Research).
Human pomegranate studies show that juice, liquid extract, and powder extract formats can lead to urinary Urolithin A glucuronide formation (Research). Human walnut and mixed-nut studies show that Urolithin A formation varies across individuals and can be linked with inflammatory or cardiometabolic biomarker patterns (Research) (Research).
This variability matters for anti-aging research because ellagitannin-rich foods do not produce the same Urolithin A exposure in every person. People with different gut-microbiota patterns may produce different urolithin metabolite profiles after similar dietary precursor intake (Research).
Direct Urolithin A used in human trials is a manufactured oral ingredient format. European Commission application-summary material describes the subject as Urolithin A and identifies it as a synthetic version structurally identical to a compound formed from ellagitannin metabolism (EFSA).
How It Behaves in the Body
In plain language, Urolithin A is studied because it may help cells manage mitochondrial quality control. Mitochondria are the structures that help cells manage energy, and aging research often examines whether mitochondrial maintenance changes with age (Research).
The main mechanism discussed in human Urolithin A research is mitophagy, which means the cell’s process for identifying and recycling damaged mitochondria. Human trials do not directly prove long-term anti-aging effects from mitophagy, but they do show changes in mitochondrial-related biomarkers after Urolithin A exposure (Research).
In the first-in-human study, Urolithin A changed plasma acylcarnitines and skeletal-muscle mitochondrial gene-expression markers after repeated 500 mg/day and 1,000 mg/day dosing. These are biological markers that help researchers evaluate mitochondrial and cellular-health pathways, not direct proof of clinical longevity benefit (Research).
Human immune-aging research has also examined mitochondrial activity inside immune cells. A 4-week randomized trial reported changes in CD8+ T-cell phenotypes, fatty-acid oxidation capacity, mitochondrial biogenesis signals, NK-cell subsets, monocyte subsets, and selected immune-cell functional readouts after 1,000 mg/day Urolithin A (Research).
What is well established from human studies is that oral Urolithin A can be absorbed and measured through circulating or urinary metabolites. What remains less established is whether those biomarker changes translate into long-term improvements in aging outcomes, disease risk, or lifespan (Research) (Review).
Absorption & Delivery Formats
Oral immediate-release: Oral intake is the main studied human route for both direct Urolithin A and ellagitannin precursor formats (Research). Direct Urolithin A produced measurable plasma exposure across tested doses, while pomegranate-derived formats produced urinary or plasma urolithin metabolites after microbial conversion (Research).
Oral extended-release: The approved human evidence does not include an extended-release Urolithin A trial. No supported conclusion can be made about extended-release anti-aging, pharmacokinetic, or tolerability effects.
Sublingual: The approved human evidence does not include sublingual Urolithin A administration. No supported claim can be made about sublingual absorption.
Transdermal: The approved human evidence does not include transdermal Urolithin A delivery. No supported claim can be made about transdermal pharmacokinetics or outcomes.
Injectable / IV: The approved human evidence does not include injectable or intravenous Urolithin A use. The available human evidence is based on oral direct intake and oral dietary precursor exposure (Research).
Quick Facts at a Glance
Onset (reported): Human studies show measurable metabolite formation after oral intake, but they do not establish a single onset time for anti-aging-related effects (Research). Dietary precursor exposures require microbial conversion, so their metabolite timing differs from direct Urolithin A exposure (Research).
Time to peak (Tmax): Human pharmacokinetic studies support measurable exposure, but the approved evidence does not provide one universal Tmax across direct Urolithin A and food-based precursor formats (Research). Tmax interpretation depends on whether Urolithin A is consumed directly or produced through gut microbial metabolism (Research).
Half-life (t½): The approved source set does not provide a single article-wide half-life value that applies to all Urolithin A formats. Urinary metabolites after pomegranate juice concentrate persisted up to 48 hours in some participants, but that finding reflects dietary precursor metabolism rather than a universal direct Urolithin A half-life (Research).
Typical duration: Direct Urolithin A studies in humans include single-dose pharmacokinetic exposure and repeated dosing from 4 weeks to 4 months (Research) (Research). Anti-aging-related immune and athletic studies include 4-week, 6-week, and 8-week designs (Research) (Research).
Absorption routes studied: Oral delivery is the studied route in the approved human evidence. Direct Urolithin A and pomegranate-derived ellagitannin formats both produce measurable metabolites, but direct Urolithin A produces more controlled exposure than food precursors (Research).
Formulation differences: Direct 500 mg Urolithin A produced higher plasma Urolithin A metabolite exposure than an 8 oz pomegranate juice challenge in a randomized crossover study (Research). Pomegranate juice, liquid extract, and powder extract produced broadly similar urinary Urolithin A glucuronide levels in a separate human comparison study (Research).
Variability drivers: Gut-microbiota composition is a major driver of Urolithin A production after ellagitannin intake, which is why studies classify people by urolithin metabotype (Research). Baseline gut-microbiota patterns also appeared to relate to vascular endothelial response in a low-dose Urolithin A trial (Research).
Tolerance / adaptation: Human trials report short-term tolerability, but tolerance or adaptation has not been established as a distinct outcome in the approved evidence (Research) (Review). Longer studies would be needed to evaluate whether responses change with prolonged exposure.
Evidence strength snapshot: Evidence is strongest for oral bioavailability, short-term safety, mitochondrial biomarker modulation, and selected muscle-function outcomes (Research) (Research). Evidence is more limited or mixed for direct longevity outcomes, cardiovascular outcomes, immune-aging implications, gut-microbiota clinical relevance, and athletic-performance endpoints (Research) (Research).
Other Physiological Contexts Studied (If Applicable)
- Exercise recovery and exertion: A runner study using 1,000 mg/day for 4 weeks did not significantly improve a 3,000-m time-trial endpoint, but reported lower perceived exertion and creatine-kinase exposure versus placebo (Research).
- Team-sport performance: A 6-week soccer-player study reported that 1,000 mg/day was feasible and well tolerated, with improvements in Yo-Yo intermittent recovery distance and countermovement jump height but no clear group-by-time effects for several other performance measures (Research).
- Bile-acid and cholesterol metabolism: A pomegranate-extract intervention in mild dyslipidemic overweight-obese individuals linked Urolithin A production with bile-acid and cholesterol-metabolism markers, but this evidence reflects dietary precursor metabolism rather than direct isolated Urolithin A effects (Research).
Safety, Interactions & Regulation
Human trials generally report Urolithin A as safe and well tolerated over studied short-to-medium durations, including first-in-human dosing and a 4-month trial in older adults (Research) (Research). A systematic review of human studies described adverse events as mild or moderate and not clearly related to Urolithin A, while emphasizing that larger and longer studies are still needed (Review).
Preclinical toxicology evidence reported no-observed-adverse-effect levels in a 90-day rat study at the highest tested doses, but animal toxicology does not replace human safety evidence (Research). Human safety interpretation should rely more heavily on clinical trials while recognizing that small studies may not detect rare adverse events or population-specific risks (Review).
The approved evidence does not identify established medication-interaction categories for Urolithin A. Evidence is also incomplete for pregnancy, lactation, pediatric use, severe kidney disease, severe liver disease, immune disease, and advanced cardiovascular disease populations because those groups are not comprehensively represented in the approved human studies (Research) (Review).
In the United States, FDA GRAS Notice Inventory entry GRN 791 lists Urolithin A with specified intended food-use categories and use levels (FDA). FDA’s response letter for GRN 791 states that FDA had no questions at that time regarding the notifier’s GRAS conclusion, and the letter also states that the response is not an FDA affirmation of GRAS status under 21 CFR 170.35 (FDA). FDA’s general GRAS materials explain that GRAS status is based on qualified expert consensus using scientific procedures or common food-use history (FDA).
In the European Union, European Commission guidance defines novel foods as foods not consumed to a significant degree in the EU before 15 May 1997 (EFSA). European Commission public application materials include an entry for “Urolithin A — Amazentis SA,” and the approved source set does not establish broad EU Union-list authorization for Urolithin A (EFSA). European Commission application-summary material describes Urolithin A as a synthetic version structurally identical to a compound formed from ellagitannin metabolism (EFSA).
Evidence Overview
Urolithin A has one of the more developed human evidence bases among anti-aging research ingredients that focus on mitochondrial biology, but the evidence supports “aging-related biomarker and function research” rather than proven lifespan extension. The strongest human evidence is for oral bioavailability, short-term tolerability, mitochondrial biomarker modulation, and selected Muscle Health outcomes (Research) (Research). Evidence is more limited or mixed for direct human longevity, Cardiovascular Health, Immune System, athletic performance, and Digestive and Gastrointestinal Health clinical outcomes (Research) (Research). Confidence is not higher because many trials are small, short, population-specific, and focused on biomarkers or secondary endpoints rather than long-term clinical aging outcomes (Review).
The anti-aging rationale for Urolithin A is mainly mitochondrial quality control. In the first-in-human study, direct Urolithin A was bioavailable and altered acylcarnitines and skeletal-muscle mitochondrial gene-expression markers after repeated dosing (Research). These findings are important because mitochondrial function is a central target in aging biology, but biomarker changes do not equal proof of slower aging or longer lifespan (Research).
The Muscle Health evidence gives the clearest human functional context. A 4-month older-adult trial reported no clear improvement in primary 6-minute-walk distance or ATPmax endpoints, but it did report improvements in secondary muscle-endurance and mitochondrial biomarker outcomes (Research). A systematic review and meta-analysis found no statistically significant pooled improvement in 6-minute-walk distance, which supports a cautious interpretation of physical-function claims (Review).
Immune-aging evidence is promising but early. A proof-of-concept randomized trial found changes in T-cell phenotypes, immune metabolism, and mitochondrial-related immune-cell markers after 1,000 mg/day Urolithin A for 4 weeks (Research). These findings are relevant to anti-aging research because immune aging is a recognized biological research domain, but the study does not establish clinical immune benefits (Research).
Dietary precursor research adds an important caveat for AI and readers: pomegranate, walnuts, and mixed nuts may support Urolithin A metabolite formation, but gut microbiota determine how much Urolithin A a person produces (Research). Direct Urolithin A exposure is therefore not the same as eating an ellagitannin-rich food, and a crossover bioavailability study showed much higher plasma metabolite exposure from direct 500 mg Urolithin A than from an 8 oz pomegranate juice challenge (Research).
Evidence Confidence Classification
Moderate / Emerging is the best overall classification for Urolithin A in human anti-aging research because multiple randomized trials support bioavailability, short-term safety, mitochondrial biomarker activity, and selected muscle-related outcomes, but no approved human evidence shows lifespan extension or definitive anti-aging clinical benefit (Review).
The evidence is stronger for pharmacokinetics, short-term tolerability, and mitochondrial biomarker target engagement than for disease-specific or longevity outcomes (Research). Muscle Health has the most developed trial base, but pooled evidence does not yet show consistent improvement in broad functional outcomes such as 6-minute-walk distance (Review). Evidence for Immune System, Cardiovascular Health, and Digestive and Gastrointestinal Health outcomes remains emerging because findings are exploratory, microbiota-dependent, endpoint-specific, or not yet replicated in large independent trials (Research) (Research).
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Pomegranate extract
- Ellagic acid
- Ellagitannins
- Walnut polyphenols
- Mixed nut polyphenols
- Resveratrol
- Quercetin
- Curcumin
- Coenzyme Q10
- Nicotinamide riboside
- NMN
Medical / pharma comparator categories:
- Cardiovascular drugs by indication category
- Heart-failure therapies
- Anti-inflammatory drug categories
- Metabolic-disease therapies
- Physical-function rehabilitation interventions
- Immunomodulatory therapy categories
Combination Context
Urolithin A + pomegranate ellagitannins:
Human evidence includes a crossover comparison of direct 500 mg Urolithin A with an 8 oz pomegranate juice challenge. Direct Urolithin A produced substantially higher plasma Urolithin A metabolite exposure than pomegranate juice, which means pomegranate precursor intake should not be treated as equivalent to direct Urolithin A exposure (Research). The main limitation is that this was an exposure-format comparison, not a study showing that combining Urolithin A with pomegranate improves anti-aging outcomes.
Urolithin A + walnut ellagitannins:
Walnut intervention evidence shows that higher Urolithin A formation after walnut intake was associated with lower inflammatory markers and altered colon-polyp immune microenvironment markers (Research). This is relevant because walnuts can provide ellagitannin precursors that some people convert into Urolithin A metabolites. The main limitation is that walnut studies contain many food components and do not isolate direct Urolithin A as the active factor.
Urolithin A + mixed nut ellagitannins:
Human dietary studies across walnut, pomegranate-extract, and mixed-nut exposures show that urolithin metabotypes differ across people and relate to cardiometabolic-risk biomarkers (Research). This supports a combination-context model in which ellagitannin-containing foods and gut microbes jointly influence Urolithin A exposure. The limitation is that these are dietary precursor contexts rather than controlled direct Urolithin A combination trials.
FAQ
What is Urolithin A?
Urolithin A is a gut-microbiota-derived metabolite formed when gut bacteria metabolize dietary ellagitannins (Research). It is studied as an anti-aging research ingredient because human trials examine mitochondrial biomarkers, muscle endurance, immune-cell aging markers, and bioavailability (Research) (Research). It should not be described as a proven anti-aging therapy because the human evidence does not show lifespan extension or disease prevention (Review).
Why is Urolithin A associated with anti-aging?
Urolithin A is associated with anti-aging because it is studied for mitochondrial quality control, a biological process that is often examined in aging research (Research). Human trials have also studied muscle endurance, immune-cell aging markers, and physical-function measures in middle-aged and older adults (Research) (Research). The evidence supports aging-related biological activity, not confirmed human longevity effects (Review).
Does Urolithin A increase lifespan in humans?
No approved human evidence shows that Urolithin A increases lifespan in humans. Human studies have measured biomarkers, muscle outcomes, immune-cell markers, vascular function, and safety rather than lifespan extension (Research) (Research). This makes Urolithin A an aging-biology research ingredient, not a proven longevity intervention (Review).
What does human research study Urolithin A for?
Human research studies Urolithin A mainly for Aging and Longevity Research, Muscle Health, Immune System, Cardiovascular Health, and Digestive and Gastrointestinal Health outcomes (Research) (Research). Direct supplementation trials measure mitochondrial biomarkers, muscle endurance, strength, immune-cell phenotypes, vascular function, and tolerability (Research) (Research). Dietary precursor studies examine how pomegranate, walnuts, and mixed nuts lead to urolithin metabolite production through gut microbes (Research).
What are the best-supported uses?
The best-supported research area is Muscle Health, especially mitochondrial biomarkers, muscle endurance, and selected strength or function-related outcomes (Research). The evidence is not conclusive because a meta-analysis found no statistically significant pooled improvement in 6-minute-walk distance across randomized trials (Review). The strongest support is for biological activity and short-term tolerability rather than established medical or anti-aging use (Research).
Where is evidence mixed or limited?
Evidence is mixed for broad physical-function outcomes, cardiovascular endpoints, athletic performance, and immune-aging implications (Research) (Research). A heart-failure crossover trial did not support clear improvement in measured echocardiographic or biochemical indices (Research). Athletic studies report different patterns across resistance-trained men, distance runners, and soccer players, so results should not be generalized across all exercise or anti-aging contexts (Research) (Research).
How quickly does Urolithin A act?
Human evidence shows measurable metabolite formation after oral intake, but it does not establish a single onset time for anti-aging effects (Research). Dietary precursor exposures require gut microbial conversion, and urinary metabolites after pomegranate juice concentrate persisted up to 48 hours in some participants (Research). Direct Urolithin A produces higher plasma metabolite exposure than pomegranate juice, but that finding does not define a universal onset for functional outcomes (Research).
What affects absorption and variability?
Absorption and exposure depend on whether Urolithin A is consumed directly or produced from dietary ellagitannins by gut microbes (Research). Direct 500 mg Urolithin A produced higher plasma metabolite exposure than an 8 oz pomegranate juice challenge in a randomized crossover study (Research). Gut-microbiota composition strongly affects Urolithin A production from ellagitannin-rich foods, which is why studies classify people by urolithin metabotype (Research).
Is tolerance reported?
Tolerance or adaptation has not been established as a distinct Urolithin A outcome in the approved human evidence. Human trials report short-term tolerability, including first-in-human dosing and 4-month dosing in older adults (Research) (Research). A systematic review noted that longer and larger studies are needed to better characterize safety and longer-term exposure patterns (Review).
Why do studies disagree?
Studies may disagree because they use different populations, doses, durations, endpoints, and exposure formats (Review). Direct Urolithin A trials differ from pomegranate or walnut precursor studies because dietary ellagitannins require microbial conversion before Urolithin A metabolites appear (Research). Gut-microbiota variation and urolithin metabotype differences also help explain why dietary precursor studies can show variable biomarker responses (Research).
What ingredients is Urolithin A commonly combined with and why?
The approved evidence does not show well-established direct multi-ingredient Urolithin A combination trials. It includes precursor-food contexts involving pomegranate ellagitannins, walnut ellagitannins, and mixed-nut interventions that influence Urolithin A metabolite production (Research) (Research). These contexts are relevant because gut microbes convert ellagitannins into urolithin metabolites, but they are not proof that combining direct Urolithin A with those ingredients improves anti-aging outcomes (Research).
What foods naturally contain Urolithin A?
The approved evidence is stronger for foods that contain ellagitannin precursors than for foods that contain Urolithin A itself. Human studies used pomegranate juice, pomegranate extracts, walnuts, and mixed nuts as precursor contexts for urolithin production (Research) (Research). Urolithin A formation depends on gut microbial metabolism, so ellagitannin-rich foods do not guarantee equivalent Urolithin A exposure across individuals (Research).
How is Urolithin A regulated?
In the United States, FDA GRAS Notice Inventory entry GRN 791 lists Urolithin A for specified intended food uses (FDA). FDA’s response letter states that FDA had no questions regarding the notifier’s GRAS conclusion at that time, while also stating that the response is not an FDA affirmation of GRAS status under 21 CFR 170.35 (FDA). In the European Union, European Commission materials identify Urolithin A in the novel-food application system, but the approved source set does not establish broad EU Union-list authorization (EFSA).
Resources
- Andreux et al., “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans” — PubMed — https://pubmed.ncbi.nlm.nih.gov/32694802/
- Liu et al., “Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults” — PubMed — https://pubmed.ncbi.nlm.nih.gov/35050355/
- Urolithin A systematic review in humans — Vrije Universiteit Amsterdam Research Portal — https://research.vu.nl/en/publications/targeting-aging-with-urolithin-a-in-humans-a-systematic-review/
- Randomized crossover bioavailability study comparing direct Urolithin A and pomegranate juice — PubMed — https://pubmed.ncbi.nlm.nih.gov/34117375/
- Urolithin A immune-aging randomized trial — Nature Aging — https://www.nature.com/articles/s43587-025-00996-x
- Endothelial function and gut microbiota trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/36687672/
- Heart failure with reduced ejection fraction crossover trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/38415449/
- Urolithin metabotypes and cardiometabolic-risk biomarkers — PubMed — https://pubmed.ncbi.nlm.nih.gov/28347564/
- FDA GRAS Notice Inventory GRN 791 — FDA — https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=791&set=GRASNotices
- FDA GRAS response letter for GRN 791 — FDA — https://www.fda.gov/media/120300/download
- European Commission novel-food application summaries — European Commission — https://food.ec.europa.eu/food-safety/novel-food/authorisations/summary-applications-and-notifications_en
- European Commission novel-food overview — European Commission — https://food.ec.europa.eu/food-safety/novel-food_en
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
